Abstract
Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: 1) plasma n-3 increased; 2) NFκB activation was suppressed in lymphocytes; 3) in vitro sensitivity of lymphocytes to doxorubicin was increased; and 4) expression of 32 genes in lymphocytes was significantly decreased.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Blood Platelets / drug effects
-
Blood Platelets / metabolism
-
Dietary Supplements
-
Doxorubicin / therapeutic use
-
Fatty Acids, Omega-3 / administration & dosage*
-
Fatty Acids, Omega-3 / adverse effects
-
Fatty Acids, Omega-3 / blood
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / blood
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
-
Lymphocytes / drug effects
-
Lymphocytes / metabolism*
-
Male
-
Middle Aged
-
NF-kappa B / antagonists & inhibitors*
-
NF-kappa B / genetics
-
NF-kappa B / metabolism
-
RNA, Messenger / genetics
Substances
-
Fatty Acids, Omega-3
-
NF-kappa B
-
RNA, Messenger
-
Doxorubicin